Which has stronger earnings & valuation, ATRC or GKOS?

AtriCure has higher earnings, but lower revenue than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AtriCure $534.53M 5.53 -$11.45M $0.21 276.67 Glaukos $612.84M 15.73 -$187.69M -$3.25 N/A

Is ATRC or GKOS more profitable?

AtriCure has a net margin of 1.85% compared to Glaukos' net margin of -30.68%. AtriCure's return on equity of 2.34% beat Glaukos' return on equity. Company Net Margins Return on Equity Return on Assets AtriCure 1.85% 2.34% 1.77% Glaukos -30.68% -6.37% -4.78%

Does the media favor ATRC or GKOS?

In the previous week, AtriCure had 6 more articles in the media than Glaukos. MarketBeat recorded 8 mentions for AtriCure and 2 mentions for Glaukos. Glaukos' average media sentiment score of 0.97 beat AtriCure's score of 0.78 indicating that Glaukos is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AtriCure 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Glaukos 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, GMED or ATRC?

Globus Medical has higher revenue and earnings than AtriCure. Globus Medical is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Globus Medical $2.94B 3.38 $537.87M $3.91 18.94 AtriCure $534.53M 5.53 -$11.45M $0.21 276.67

Does the media prefer GMED or ATRC?

In the previous week, AtriCure had 1 more articles in the media than Globus Medical. MarketBeat recorded 8 mentions for AtriCure and 7 mentions for Globus Medical. Globus Medical's average media sentiment score of 0.89 beat AtriCure's score of 0.78 indicating that Globus Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Globus Medical 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AtriCure 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, ATRC or PODD?

Insulet has higher revenue and earnings than AtriCure. Insulet is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AtriCure $534.53M 5.53 -$11.45M $0.21 276.67 Insulet $2.71B 3.60 $247.10M $5.35 26.28

Is ATRC or PODD more profitable?

Insulet has a net margin of 12.29% compared to AtriCure's net margin of 1.85%. Insulet's return on equity of 29.29% beat AtriCure's return on equity. Company Net Margins Return on Equity Return on Assets AtriCure 1.85% 2.34% 1.77% Insulet 12.29% 29.29% 13.31%

Does the media prefer ATRC or PODD?

In the previous week, AtriCure had 4 more articles in the media than Insulet. MarketBeat recorded 8 mentions for AtriCure and 4 mentions for Insulet. Insulet's average media sentiment score of 0.95 beat AtriCure's score of 0.78 indicating that Insulet is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AtriCure 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insulet 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ATRC or MMED?

In the previous week, AtriCure had 4 more articles in the media than MiniMed Group. MarketBeat recorded 8 mentions for AtriCure and 4 mentions for MiniMed Group. AtriCure's average media sentiment score of 0.78 beat MiniMed Group's score of 0.26 indicating that AtriCure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AtriCure 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MiniMed Group 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, TFX or ATRC?

AtriCure has lower revenue, but higher earnings than Teleflex. Teleflex is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Teleflex $1.99B 2.65 -$905.64M -$23.29 N/A AtriCure $534.53M 5.53 -$11.45M $0.21 276.67

Is TFX or ATRC more profitable?

AtriCure has a net margin of 1.85% compared to Teleflex's net margin of -39.67%. Teleflex's return on equity of 11.93% beat AtriCure's return on equity. Company Net Margins Return on Equity Return on Assets Teleflex -39.67% 11.93% 5.44% AtriCure 1.85% 2.34% 1.77%

Does the media refer more to TFX or ATRC?

In the previous week, AtriCure had 5 more articles in the media than Teleflex. MarketBeat recorded 8 mentions for AtriCure and 3 mentions for Teleflex. Teleflex's average media sentiment score of 1.15 beat AtriCure's score of 0.78 indicating that Teleflex is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teleflex 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AtriCure 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

AtriCure (ATRC) Competitors

$58.10 -1.02 (-1.73%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$58.13 +0.03 (+0.05%)

As of 09/18/2026 07:30 PM Eastern

Compare

ATRC vs. GKOS, GMED, PODD, MMED, and TFX

Should you buy AtriCure stock or one of its competitors? AtriCure's main competitors and comparable companies include Glaukos (GKOS), Globus Medical (GMED), Insulet (PODD), MiniMed Group (MMED), and Teleflex (TFX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does AtriCure compare to Glaukos?

AtriCure (NASDAQ:ATRC) and Glaukos (NYSE:GKOS) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

AtriCure has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market. Comparatively, Glaukos has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market.

AtriCure has a net margin of 1.85% compared to Glaukos' net margin of -30.68%. AtriCure's return on equity of 2.34% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AtriCure	1.85%	2.34%	1.77%
Glaukos	-30.68%	-6.37%	-4.78%

In the previous week, AtriCure had 6 more articles in the media than Glaukos. MarketBeat recorded 8 mentions for AtriCure and 2 mentions for Glaukos. Glaukos' average media sentiment score of 0.97 beat AtriCure's score of 0.78 indicating that Glaukos is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AtriCure	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Glaukos	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.1% of AtriCure shares are owned by institutional investors. Comparatively, 99.0% of Glaukos shares are owned by institutional investors. 4.0% of AtriCure shares are owned by insiders. Comparatively, 5.9% of Glaukos shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

AtriCure has higher earnings, but lower revenue than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AtriCure	$534.53M	5.53	-$11.45M	$0.21	276.67
Glaukos	$612.84M	15.73	-$187.69M	-$3.25	N/A

AtriCure presently has a consensus target price of $53.30, indicating a potential downside of 8.26%. Glaukos has a consensus target price of $178.08, indicating a potential upside of 8.99%. Given Glaukos' stronger consensus rating and higher probable upside, analysts clearly believe Glaukos is more favorable than AtriCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AtriCure	0 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.75
Glaukos	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

Summary

AtriCure beats Glaukos on 10 of the 17 factors compared between the two stocks.

How does AtriCure compare to Globus Medical?

Globus Medical (NYSE:GMED) and AtriCure (NASDAQ:ATRC) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

Globus Medical presently has a consensus price target of $101.77, indicating a potential upside of 37.41%. AtriCure has a consensus price target of $53.30, indicating a potential downside of 8.26%. Given Globus Medical's stronger consensus rating and higher probable upside, research analysts clearly believe Globus Medical is more favorable than AtriCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Globus Medical	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	2.88
AtriCure	0 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, AtriCure had 1 more articles in the media than Globus Medical. MarketBeat recorded 8 mentions for AtriCure and 7 mentions for Globus Medical. Globus Medical's average media sentiment score of 0.89 beat AtriCure's score of 0.78 indicating that Globus Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Globus Medical	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AtriCure	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Globus Medical has a net margin of 17.02% compared to AtriCure's net margin of 1.85%. Globus Medical's return on equity of 14.57% beat AtriCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Globus Medical	17.02%	14.57%	12.62%
AtriCure	1.85%	2.34%	1.77%

Globus Medical has higher revenue and earnings than AtriCure. Globus Medical is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Globus Medical	$2.94B	3.38	$537.87M	$3.91	18.94
AtriCure	$534.53M	5.53	-$11.45M	$0.21	276.67

95.2% of Globus Medical shares are owned by institutional investors. Comparatively, 99.1% of AtriCure shares are owned by institutional investors. 18.4% of Globus Medical shares are owned by insiders. Comparatively, 4.0% of AtriCure shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Globus Medical has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market. Comparatively, AtriCure has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market.

Summary

Globus Medical beats AtriCure on 12 of the 17 factors compared between the two stocks.

How does AtriCure compare to Insulet?

AtriCure (NASDAQ:ATRC) and Insulet (NASDAQ:PODD) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings.

AtriCure has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market. Comparatively, Insulet has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market.

AtriCure presently has a consensus price target of $53.30, suggesting a potential downside of 8.26%. Insulet has a consensus price target of $195.40, suggesting a potential upside of 38.98%. Given Insulet's higher probable upside, analysts clearly believe Insulet is more favorable than AtriCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AtriCure	0 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.75
Insulet	2 Sell rating(s)	11 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.42

In the previous week, AtriCure had 4 more articles in the media than Insulet. MarketBeat recorded 8 mentions for AtriCure and 4 mentions for Insulet. Insulet's average media sentiment score of 0.95 beat AtriCure's score of 0.78 indicating that Insulet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AtriCure	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insulet	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Insulet has higher revenue and earnings than AtriCure. Insulet is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AtriCure	$534.53M	5.53	-$11.45M	$0.21	276.67
Insulet	$2.71B	3.60	$247.10M	$5.35	26.28

99.1% of AtriCure shares are held by institutional investors. 4.0% of AtriCure shares are held by company insiders. Comparatively, 0.4% of Insulet shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Insulet has a net margin of 12.29% compared to AtriCure's net margin of 1.85%. Insulet's return on equity of 29.29% beat AtriCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AtriCure	1.85%	2.34%	1.77%
Insulet	12.29%	29.29%	13.31%

Summary

Insulet beats AtriCure on 9 of the 17 factors compared between the two stocks.

How does AtriCure compare to MiniMed Group?

AtriCure (NASDAQ:ATRC) and MiniMed Group (NASDAQ:MMED) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

In the previous week, AtriCure had 4 more articles in the media than MiniMed Group. MarketBeat recorded 8 mentions for AtriCure and 4 mentions for MiniMed Group. AtriCure's average media sentiment score of 0.78 beat MiniMed Group's score of 0.26 indicating that AtriCure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AtriCure	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MiniMed Group	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

AtriCure has higher earnings, but lower revenue than MiniMed Group. MiniMed Group is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AtriCure	$534.53M	5.53	-$11.45M	$0.21	276.67
MiniMed Group	$3.10B	1.97	-$333M	-$0.68	N/A

AtriCure has a net margin of 1.85% compared to MiniMed Group's net margin of 0.00%. AtriCure's return on equity of 2.34% beat MiniMed Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AtriCure	1.85%	2.34%	1.77%
MiniMed Group	N/A	N/A	N/A

AtriCure presently has a consensus target price of $53.30, suggesting a potential downside of 8.26%. MiniMed Group has a consensus target price of $23.77, suggesting a potential upside of 9.16%. Given MiniMed Group's higher probable upside, analysts plainly believe MiniMed Group is more favorable than AtriCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AtriCure	0 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.75
MiniMed Group	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

99.1% of AtriCure shares are held by institutional investors. 4.0% of AtriCure shares are held by company insiders. Comparatively, 0.0% of MiniMed Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

AtriCure beats MiniMed Group on 12 of the 15 factors compared between the two stocks.

How does AtriCure compare to Teleflex?

Teleflex (NYSE:TFX) and AtriCure (NASDAQ:ATRC) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

AtriCure has lower revenue, but higher earnings than Teleflex. Teleflex is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teleflex	$1.99B	2.65	-$905.64M	-$23.29	N/A
AtriCure	$534.53M	5.53	-$11.45M	$0.21	276.67

95.6% of Teleflex shares are owned by institutional investors. Comparatively, 99.1% of AtriCure shares are owned by institutional investors. 0.7% of Teleflex shares are owned by company insiders. Comparatively, 4.0% of AtriCure shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Teleflex currently has a consensus price target of $152.90, suggesting a potential upside of 22.82%. AtriCure has a consensus price target of $53.30, suggesting a potential downside of 8.26%. Given Teleflex's higher possible upside, equities research analysts clearly believe Teleflex is more favorable than AtriCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teleflex	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.42
AtriCure	0 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, AtriCure had 5 more articles in the media than Teleflex. MarketBeat recorded 8 mentions for AtriCure and 3 mentions for Teleflex. Teleflex's average media sentiment score of 1.15 beat AtriCure's score of 0.78 indicating that Teleflex is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teleflex	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AtriCure	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Teleflex has a beta of 0.82, meaning that its share price is 18% less volatile than the broader market. Comparatively, AtriCure has a beta of 1.26, meaning that its share price is 26% more volatile than the broader market.

AtriCure has a net margin of 1.85% compared to Teleflex's net margin of -39.67%. Teleflex's return on equity of 11.93% beat AtriCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teleflex	-39.67%	11.93%	5.44%
AtriCure	1.85%	2.34%	1.77%

Summary

AtriCure beats Teleflex on 11 of the 16 factors compared between the two stocks.

Get AtriCure News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATRC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATRC vs. The Competition

Export

Metric	AtriCure	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.01B	$5.53B	$7.25B	$13.13B
Dividend Yield	N/A	1.79%	2.57%	12.94%
P/E Ratio	276.68	25.11	273.81	25.39
Price / Sales	5.53	72.24	692.78	114.04
Price / Cash	188.89	32.72	77.42	51.66
Price / Book	5.87	5.74	10.45	6.33
Net Income	-$11.45M	$151.55M	$3.48B	$358.24M
7 Day Performance	6.53%	0.66%	0.88%	1.17%
1 Month Performance	22.03%	-3.84%	-1.59%	-2.59%
1 Year Performance	59.48%	6.85%	18.08%	5.97%

AtriCure Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATRC AtriCure	2.498 of 5 stars	$58.10 -1.7%	$53.30 -8.3%	+58.5%	$3.01B	$534.53M	276.68	1,350	Analyst Forecast High Trading Volume
GKOS Glaukos	2.2021 of 5 stars	$171.19 +0.1%	$178.08 +4.0%	+90.4%	$10.10B	$507.44M	N/A	1,094
GMED Globus Medical	4.6011 of 5 stars	$75.10 -0.9%	$101.77 +35.5%	+30.6%	$10.08B	$2.94B	19.19	6,000	Analyst Forecast Insider Trade
PODD Insulet	4.0729 of 5 stars	$138.83 +0.7%	$195.40 +40.8%	-57.8%	$9.61B	$3.05B	25.89	5,400
MMED MiniMed Group	1.5347 of 5 stars	$22.16 +0.8%	$23.77 +7.3%	N/A	$6.23B	$3.22B	N/A	2,800	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATRC) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AtriCure (ATRC) Competitors